Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on shionogi.com
Leave the platform to read the original full article on the publisher site.
Source: Shionogi (IR News)
Scope: Industry
Related coverage
More related coverage
Exdensur (depemokimab) approved in China for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP)
Exdensur is the first and only ultra-long-acting biologic in China for CRSwNP
FDA Seeks Input on Digital Health Technologies in Clinical Investigations for Drugs and Biological Products
By Adrienne R. Lenz, Principal Medical Device Regulation Expert —
Notice Regarding Issuance of New Shares and Secondary Offering of Shares
Print（PDF/217KB） Apr. 08, 2026 Finances Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Re...
Notice Regarding Refinancing of Existing Borrowings through a Bridge Loan
Print（PDF/186KB） Apr. 08, 2026 Finances Sumitomo Pharma Co., Ltd. (Head Office: Osaka, Japan; Re...